Scientists headed by a team at the University of British Columbia (UBC) have developed a new approach to drug design that can deliver therapeutics directly to a specific part of the gastrointestinal ...

Nanoparticles enhance drug solubility, stability, and bioavailability, improving therapeutic outcomes for GI conditions like IBD through targeted delivery mechanisms. Hydrogel-based systems offer ...

Please provide your email address to receive an email when new articles are posted on . There were several important FDA approvals for GI conditions over the past year, including the first treatment ...

Still life of Wegovy an injectable prescription weight loss medicine that has helped people with obesity. It should be used with a weight loss plan and physical activity. (Photo by: Michael ...

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives ...

Among the most recently approved drugs for weight management, glucagon-like peptide 1 (GLP-1) agonists have garnered considerable attention; however, the effects of these drugs on the gastrointestinal ...

Semaglutide, tirzepatide, and dulaglutide have similar gastrointestinal safety profiles among patients with type 2 diabetes (T2D), an active-comparator cohort study showed. “We were somewhat surprised ...

The designation is supported by data from the 12-week, randomized, double-blind phase 2 FILLMORE trial. The Food and Drug Administration (FDA) has granted Orphan Drug designation to AMT-101 for the ...

An oral medication already approved for thrombocytopenia in patients with liver disease significantly improved platelet ...

When used as a weight-loss tool, the glucagon-like peptide-1 (GLP-1) receptor agonists semaglutide (Ozempic) and liraglutide (Saxenda), both sold by Novo Nordisk, raise the odds that patients will ...

Ironwood Pharmaceuticals, a company whose drug research yielded a blockbuster gastrointestinal disorder drug, has struck a $1 billion deal to acquire VectivBio, a biotech whose lead program brings ...